MRI Characteristics of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Importance Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a demyelinating disease distinct from multiple sclerosis (MS) and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+NMOSD). Magnetic resonance imaging (MRI) is central to confirming attacks, defining lesion distribution, and excluding alternative diagnoses and is a key component of the 2023 MOGAD diagnostic criteria. However, its imaging spectrum and lesion evolution remain underrecognized in practice, and variability in imaging parameters can contribute to delayed diagnosis and suboptimal treatment. Observations This article summarizes the hallmark MRI features of optic nerve, brain, and spinal cord involvement in MOGAD, including key findings from the 2023 diagnostic criteria, supported by illustrative figures and detailed tables. The characteristic evolution of MRI abnormalities in MOGAD is highlighted, including radiologic lag, lesion dynamics during acute attacks, and frequent T2-lesion resolution, contrasting with the persistent lesions typical of MS. A recommended MRI protocol for acute attacks is proposed, and the timing and utility of rebaselining MRI (ie, repeating the MRI to establish a new baseline) after onset are reviewed. The clinical course of MOGAD is of attack-related neuroinflammation evident clinically and radiologically, and asymptomatic radiological activity is rare, suggesting that surveillance MRI has less clinical utility than in MS and less value as a surrogate biomarker in clinical trials. MRI features that differentiate MOGAD from MS and AQP4+NMOSD are summarized and imaging red flags suggestive of alternative diagnoses are highlighted. Finally, emerging advanced imaging, artificial intelligence in MOGAD imaging, and the link between imaging and immunopathogenesis are reviewed. Conclusions and Relevance MRI is central to MOGAD evaluation, and recognition of the characteristic imaging features and lesion dynamics outlined in this review can aid diagnosis. Application of the standardized MRI protocol summarized here can optimize use in clinical practice and promote harmonization across research studies. Future imaging and artificial intelligence applications may improve diagnosis, disease monitoring, and understanding of MOGAD pathogenesis.

Authors

Institutions

Publication Details

Journal
JAMA Neurology
Published
2026-09-28
DOI
https://doi.org/10.1001/jamaneurol.2026.3196
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

MRI Characteristics of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Maciej Juryńczyk, Laura Cacciaguerra, Yael Hacohen, Rosa Cortese et al.
JAMA Neurology
Multiple Sclerosis Research Studies
article

MRI Characteristics of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Maciej Juryńczyk, Laura Cacciaguerra, Yael Hacohen, Rosa Cortese, Eoin P. Flanagan, Ruth Geraldes, Friedemann Paul, Àlex Rovira, Kazuo Fujihara, Silvia Messina, Giulia Fadda, Sudarshini Ramanathan, Elia Sechi, Silvia Tenembaum, Michael Levy, John J. Chen, Jacqueline Palace, Brenda L. Banwell, Romain Marignier, Kshitij Mankad, Ho Jin Kim, Edgar Carnero Contentti
article en

Abstract

Importance Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a demyelinating disease distinct from multiple sclerosis (MS) and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+NMOSD). Magnetic resonance imaging (MRI) is central to confirming attacks, defining lesion distribution, and excluding alternative diagnoses and is a key component of the 2023 MOGAD diagnostic criteria. However, its imaging spectrum and lesion evolution remain underrecognized in practice, and variability in imaging parameters can contribute to delayed diagnosis and suboptimal treatment. Observations This article summarizes the hallmark MRI features of optic nerve, brain, and spinal cord involvement in MOGAD, including key findings from the 2023 diagnostic criteria, supported by illustrative figures and detailed tables. The characteristic evolution of MRI abnormalities in MOGAD is highlighted, including radiologic lag, lesion dynamics during acute attacks, and frequent T2-lesion resolution, contrasting with the persistent lesions typical of MS. A recommended MRI protocol for acute attacks is proposed, and the timing and utility of rebaselining MRI (ie, repeating the MRI to establish a new baseline) after onset are reviewed. The clinical course of MOGAD is of attack-related neuroinflammation evident clinically and radiologically, and asymptomatic radiological activity is rare, suggesting that surveillance MRI has less clinical utility than in MS and less value as a surrogate biomarker in clinical trials. MRI features that differentiate MOGAD from MS and AQP4+NMOSD are summarized and imaging red flags suggestive of alternative diagnoses are highlighted. Finally, emerging advanced imaging, artificial intelligence in MOGAD imaging, and the link between imaging and immunopathogenesis are reviewed. Conclusions and Relevance MRI is central to MOGAD evaluation, and recognition of the characteristic imaging features and lesion dynamics outlined in this review can aid diagnosis. Application of the standardized MRI protocol summarized here can optimize use in clinical practice and promote harmonization across research studies. Future imaging and artificial intelligence applications may improve diagnosis, disease monitoring, and understanding of MOGAD pathogenesis.

JAMA Neurology
Université Claude Bernard Lyon 1 (FR), University of Siena (IT), Universitat Autònoma de Barcelona (ES), Fukushima Medical University (JP), Mayo Clinic (US), Harvard University (US), Johns Hopkins University (US), University of Ottawa (CA), University of Sassari (IT), Instytut Biologii Doświadczalnej im. Marcelego Nenckiego (PL), University of Basel (CH), Max Delbrück Center (DE), Garrahan Hospital (AR), Great Ormond Street Hospital (GB), Concord Repatriation General Hospital (AU), Great Ormond Street Hospital for Children NHS Foundation Trust (GB), University Hospital of Basel (CH), University of Oxford (GB), Massachusetts General Hospital (US), Centre de Recherche en Neurosciences de Lyon (FR), Hospices Civils de Lyon (FR), Hôpital Pierre Wertheimer (FR), National Cancer Center (KR), Instituto de Neurología Cognitiva (AR), Mayo Clinic in Arizona (US), Vall d'Hebron Hospital Universitari (ES), Hospital Alemán (AR), Oxford University Hospitals NHS Trust (GB), National Hospital for Neurology and Neurosurgery (GB), Anzac Research Institute (AU), Ottawa Hospital Research Institute (CA), UCL Queen Square Institute of Neurology (GB), National Cancer Center Hospital (KR), University College London (GB), Charité - Universitätsmedizin Berlin (DE), Polish Academy of Sciences (PL)
Openalex Percentile: Top 12%
Multiple Sclerosis Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.